Provided by Tiger Trade Technology Pte. Ltd.

Cognition Therapeutics, Inc

1.05
+0.04003.96%
Pre-market: 1.03-0.0237-2.26%05:26 EDT
Volume:377.80K
Turnover:393.29K
Market Cap:99.85M
PE:-5.42
High:1.07
Open:1.01
Low:1.01
Close:1.01
52wk High:2.67
52wk Low:0.5501
Shares:95.09M
Float Shares:85.42M
Volume Ratio:1.10
T/O Rate:0.44%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1936
EPS(LYR):-0.3228
ROE:-83.76%
ROA:-78.18%
PB:3.02
PE(LYR):-3.25

Loading ...

Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045

GlobeNewswire
·
Jun 16

Cognition Therapeutics (CGTX) Gets a Buy from H.C. Wainwright

TIPRANKS
·
Jun 09

Cognition Therapeutics Advances Zervimesine Toward Phase 3 DLB Trial

TIPRANKS
·
Jun 04

Cognition Therapeutics CEO presents at Jefferies Global Healthcare Conference

Reuters
·
Jun 01

Cognition Therapeutics Participating in Upcoming Investor Conferences

GlobeNewswire
·
Jun 01

Peter Thiel-Backed AI Coding Startup Cognition Hits $26 Billion Valuation

Dow Jones
·
May 28

KDventures Portfolio Firm Highlights Severe Fatigue as Key Unmet Need in PBC

TIPRANKS
·
May 27

Cognition Therapeutics Advances Zervimesine Toward Late-Stage DLB Trial

TIPRANKS
·
May 21

Cognition Therapeutics plans late-stage zervimesine trial for Lewy body dementia psychosis

Reuters
·
May 21

Cognition Therapeutics Completes Meeting With FDA for Zervimesine (Ct1812) in Dementia With Lewy Bodies With Psychosis

THOMSON REUTERS
·
May 21

Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis

GlobeNewswire
·
May 21

Press Release: Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

Dow Jones
·
May 14

Analysts Offer Insights on Healthcare Companies: Rockwell Med (RMTI), 4D Molecular Therapeutics (FDMT) and Cognition Therapeutics (CGTX)

TIPRANKS
·
May 09

Cognition Therapeutics reports Q1 EPS (5c), consensus (7c)

TIPRANKS
·
May 08

Cognition Therapeutics Q1 EPS $(0.05) Beats $(0.06) Estimate

Benzinga Earnings
·
May 08

Cognition Therapeutics Q1 net loss narrows on lower expenses

Reuters
·
May 08

Press Release: Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update

Dow Jones
·
May 08

Cognition Therapeutics Inc expected to post a loss of 7 cents a share - Earnings Preview

Reuters
·
May 01

Top Brass Makes Bold Move With Fresh Insider Buying Spree at Cognition Therapeutics

TIPRANKS
·
Apr 21

Cognition Therapeutics CEO Lisa Ricciardi buys 9,175 shares for $10,092.50

Reuters
·
Apr 21